Fremanezumab clinical trials
Also written TEV-48125 and Ajovy.
How each study uses fremanezumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the fremanezumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 14 Sept 2018 · AJOVY · BLA 761089 (FDA, Drugs@FDA)
- European Union
- 28 Mar 2019 · Ajovy · EMEA/H/C/004833 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
27 studies that test it; most in 2017 (8); 2 more planned to start later
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2014 | 2 |
| 2016 | 3 |
| 2017 | 8 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 23 · Other 6
Teva Branded Pharmaceutical Products R&D, Inc. (17) · Otsuka Pharmaceutical Co., Ltd. (3) · Brigham and Women's Hospital (1) · Teva Branded Pharmaceutical Products R&D LLC (1) · David True (1) · M.D. Anderson Cancer Center (1) · Insel Gruppe AG, University Hospital Bern (1) · Beth Israel Deaconess Medical Center (1)
Often tested with
Tested in the same studies.
Prednisone (1) · Eptinezumab (1) · Erenumab (1) · Onabotulinum toxin A (1) · Botulinum toxin type A (1) · Galcanezumab (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test fremanezumab.
- Jul 2027Calcitonin Gene-related Peptide Antibody in Acute Mountain SicknessPhase 4 · Insel Gruppe AG, University Hospital Bern
Studies
Open first, then newest update. How each study uses fremanezumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 29
- Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)Not yet recruitingPhase 1M.D. Anderson Cancer CenterNCT07832266Written as AjovyHow we know
- Calcitonin Gene-related Peptide Antibody in Acute Mountain SicknessNot yet recruitingPhase 4Insel Gruppe AG, University Hospital BernNCT07653516Written as Fremanezumab 225 Mg/1.5 mL Subcutaneous SolutionHow we know
- Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45CompletedPhase 4Brigham and Women's HospitalNCT06173661Written as FremanezumabHow we know
- A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and AdolescentsCompletedPhase 3Teva Branded Pharmaceutical Products R&D LLCNCT04530110Written as FremanezumabHow we know
- A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of AgeCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT04458857Written as FremanezumabHow we know
- Fremanezumab, Migraine and SleepTerminatedPhase 4Beth Israel Deaconess Medical CenterNCT04693533Written as Fremanezumab Prefilled Syringe [Ajovy]How we know
- A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of AgeCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT04464707Written as FremanezumabHow we know
- A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With MigraineCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT05458011Written as FremanezumabHow we know
- Real World Effectiveness of Eptinezumab in Participants With MigraineTerminatedPhase 4H. Lundbeck A/SNCT05284019Written as FremanezumabHow we know
- A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive DisorderCompletedPhase 4Teva Branded Pharmaceutical Products R&D, Inc.NCT04041284Written as FremanezumabHow we know
- A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With FibromyalgiaTerminatedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT03965091Written as FremanezumabHow we know
- Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of MigraineCompletedPhase 3Otsuka Pharmaceutical Co., Ltd.NCT03303105Written as TEV-48125How we know
- A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)CompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT03347188Written as FremanezumabHow we know
- Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related BurdenCompletedPhase 4David TrueNCT04461795Written as Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]How we know
- Safety and Efficacy of Fremanezumab for Migraine in Adult CADASILWithdrawnPhase 2Mayo ClinicNCT04334408Written as FremanezumabHow we know
- A Multicenter Assessment of LBR-101 in High Frequency Episodic MigraineCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT02025556Written as LBR-101 High DoseHow we know
- Assessment of LBR-101 In Chronic MigraineCompletedPhase 2Teva Branded Pharmaceutical Products R&D, Inc.NCT02021773Written as LBR-101 High DoseHow we know
- Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic MigraineCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT02621931Written as FremanezumabHow we know
- An Efficacy and Safety Study of Fremanezumab in Adults With MigraineCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT03308968Written as FremanezumabHow we know
- Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of MigraineCompletedPhase 3Teva Branded Pharmaceutical Products R&D, Inc.NCT02638103Written as FremanezumabHow we know
Codes
What other systems call fremanezumab · ClinicalTrials.gg INT000387
- UNII (FDA) PF8K38CG54FREMANEZUMABConfirmed FDA, Wikidata
- RxNorm 2056691Confirmed FDA, Wikidata
- Wikidata Q39048381fremanezumabConfirmed FDA, Wikidata
- NCI Thesaurus C174842FremanezumabOne source FDA
- DrugBank DB14041One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | PF8K38CG54 | FREMANEZUMAB | Confirmed FDA, Wikidata |
| RxNorm | 2056691 | — | Confirmed FDA, Wikidata |
| Wikidata | Q39048381 | fremanezumab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C174842 | Fremanezumab | One source FDA |
| DrugBank | DB14041 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.